Se connecter Inscription gratuite

Last updated: 18 July 2019 at 3:53pm EST

Lyle Arnold Net Worth




The estimated Net Worth of Lyle J Arnold is at least $316 millier dollars as of 19 October 2016. Lyle Arnold owns over 45,000 units of Biocept Inc stock worth over $28,372 and over the last 10 years he sold BIOC stock worth over $0. In addition, he makes $287,428 as Senior Vice President - Research & Development et Chief Scientific Officer at Biocept Inc.

Lyle Arnold BIOC stock SEC Form 4 insiders trading

Lyle has made over 1 trades of the Biocept Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 45,000 units of BIOC stock worth $49,500 on 19 October 2016.

The largest trade he's ever made was buying 45,000 units of Biocept Inc stock on 19 October 2016 worth over $49,500. On average, Lyle trades about 5,000 units every 0 days since 2014. As of 19 October 2016 he still owns at least 65,238 units of Biocept Inc stock.

You can see the complete history of Lyle Arnold stock trades at the bottom of the page.





Lyle Arnold biography

Dr. Lyle J. Arnold Ph. D. serves as Senior Vice President - Research & Development, Chief Scientific Officer of the Company. Dr. Arnold is a biotechnology executive, entrepreneur, and developer of innovative technologies covering therapeutics, molecular diagnostics, and genomics. Prior to joining Biocept, Dr. Arnold founded Aegea Biotechnologies to acquire, develop, and commercialize, next generation nucleic acid technologies. Dr. Arnold has served on the board of directors of numerous companies, including Asuragen and Aegea, as well as, non-profit organizations. Dr. Arnold has also held senior scientific and management positions at Molecular Biosystems (co-founder), Genta, Synteni, Incyte Genomics, Oasis Biosciences (co-founder), and Gen-Probe (now Hologic). In addition, Dr. Arnold was a faculty member in the UCSD School of Medicine and a member of the UCSD Cancer Center. Dr. Arnold is an inventor or co-inventor on 49 issued U.S. patents and more than 160 issued and pending patents worldwide. He is the principal inventor of the chemiluminescent Hybridization Protection Assay (HPA) and associated technologies core to Hologic assays that generate more than $500 million in product revenue annually. Dr. Arnold is also the inventor of the patented Switch-Blocker technology for detecting extremely rare genetic events that Biocept uses for interrogating ctDNA for cancer associated mutations. In addition, he has authored more than 50 scientific publications. Dr. Arnold received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.

What is the salary of Lyle Arnold?

As the Senior Vice President - Research & Development et Chief Scientific Officer of Biocept Inc, the total compensation of Lyle Arnold at Biocept Inc is $287,428. There are 3 executives at Biocept Inc getting paid more, with Michael Nall having the highest compensation of $1,216,060.



How old is Lyle Arnold?

Lyle Arnold is 73, he's been the Senior Vice President - Research & Development et Chief Scientific Officer of Biocept Inc since 2011. There are 4 older and 15 younger executives at Biocept Inc. The oldest executive at Biocept Inc is Margaret Faye Wilson, 82, who is the Lead Independent Director.

What's Lyle Arnold's mailing address?

Lyle's mailing address filed with the SEC is 5810 Nancy Ridge Dr # 150, San Diego, CA 92121, USA.

Insiders trading at Biocept Inc

Over the last 11 years, insiders at Biocept Inc have traded over $2,456 worth of Biocept Inc stock and bought 1,703,300 units worth $1,869,312 . The most active insiders traders include Claire Reiss, Edward A. Neff et David F Hale. On average, Biocept Inc executives and independent directors trade stock every 92 days with the average trade being worth of $27,462. The most recent stock trade was executed by David F Hale on 9 December 2021, trading 445 units of BIOC stock currently worth $1,807.



What does Biocept Inc do?

biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar



What does Biocept Inc's logo look like?

Biocept Inc logo

Complete history of Lyle Arnold stock trades at Biocept Inc

Date
#
Société
 Initié
Trans.
Transaction
 Actions Prix par action Prix ​​total Actions après Source
19 Oct 2016 BIOC Biocept Inc Lyle J Arnold
Vice-président senior et Chief Scientific Officer
 Acheter 45,000 $1.10 $49,500
19 Oct 2016
65,238 ↗


Biocept Inc executives and stock owners

Biocept Inc executives and other stock owners filed with the SEC include: